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Università degli Studi di Milano, Milano, ItalyAbstractMolecular methods to differentiate serotypes, mating types and
molecular types of Cryptococcus neoformans and C. gattii are
important tools to understand epidemiology and pathogenesis of
these pathogens. In this study, a multiplex polymerase chain
reaction (PCR) approach was applied to sero-mating typing of
C. gattii strains. Four pairs of primers were designed to target 4
allele-speciﬁc genes located in the mating-type locus. Twenty-
three C. gattii strains, presenting different mating types and
serotypes, were tested to validate the method. The method was
able to identify all sero-mating allelic patterns including hybrid
combinations, and therefore, it represents a simple one-step PCR
for sero-mating typing of C. gattii strains.
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E-mail: massimo.cogliati@unimi.itIntroductionCryptococcus neoformans and C. gattii are the etiological agents of
cryptococcosis causing more than 1 million cases every year
worldwide. The disease is mainly associated with HIV infection,Microbiol Infect 2015; 21: 190.e1–190.e4
nical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect
p://dx.doi.org/10.1016/j.cmi.2014.09.003but recently an increasing number of cases among non–HIV-
infected patients have been observed. Furthermore, C. gattii is
causing an outbreak in Vancouver Island and the near North
Paciﬁc area, and other cases have been reported in Europe,
revealing that this pathogen is not restricted to subtropical
areas [1,2].
Differences in biology, epidemiology, pathogenicity, clinical
manifestations and drug susceptibility have been observed be-
tween the 2 species [3]. Although they are morphologically
indistinguishable, they can be easily differentiated by cultivation
on L-canavanine-glycine-bromothymol blue agar medium [4].
Until 2004, the commercial availability of a serological kit
(Crypto Check, Iatron Labs, Tokyo) allowed the identiﬁcation
of 5 serotypes: A, D and AD among C. neoformans, and B and C
among C. gattii. After the production and distribution of the kit
was discontinued, serotyping was no longer possible and
alternative molecular methods were evaluated.
Comparison of different molecular techniques [5–8] showed
that C. neoformans is divided into 5 molecular types: VNI, VNII
and VNB corresponding to C. neoformans var. grubii, serotype A;
VNIV corresponding to C. neoformans var. neoformans, serotype
D; and VNIII including diploid and aneuploid hybrids of the 2
varieties. C. gattii is divided into 4 molecular types named VGI,
VGII, VGIII and VGIV that do not correlate to serotype B or C.
Furthermore, both Cryptococcus species have a bipolar sexual
cycle including MATa and MATα strains, the latter being more
prevalent among both clinical and environmental isolates [3].
Because differences in virulence between MATα and MATa
strains were observed [9–11], mating type locus genes were
intensively studied to understand their role in pathogenesis.
Deletion or disruption of genes embedded in the mating type
locus, such as MF, STE3, STE20, STE11, and STE12 genes,
resulted in altered virulence in murine model infections
[12–15]. Therefore, molecular methods to differentiate sero-
types, mating types and molecular types represent important
tools to understand the epidemiology and the pathogenesis of
C. neoformans and C. gattii.
In a previous study [16], we developed a multiplex poly-
merase chain reaction (PCR) able to identify simultaneously the
sero-mating type allelic pattern of C. neoformans strains.
Multiplex mix included 4 pair of primers speciﬁcally designed to
amplify the 4 mating type alleles of C. neoformans: αA, aA, αD,
and aD. In addition, the different hybrid combinations (αADa
and aADα) could be distinguished.
In the present study, we applied the same approach to
develop a new multiplex PCR method for sero-mating typing of
C. gattii. Four pairs of primers were designed on the basis of
reference strains sequences obtained by GenBank (www.ncbi.
nlm.nih.gov): NIH312 αC (HQ396150), WM276 αBious Diseases. Published by Elsevier Ltd. All rights reserved
CMI Cogliati et al. Cogliati et al. Cryptococcus gattii sero-mating type allelic pattern 190.e2(AY710430), E566 aB (AY710429), B4546 aC (HQ396149).
The multiplex target genes, all included in the mating type locus,
were VPS26α for αB allele, GEF1α for αC allele, GEF1a for aC
allele, and STE12a for aB allele (Fig. 1a). The ampliﬁcation re-
action mix contained buffer 1X (Tris-HCl, KCl, (NH4)2SO4,
1.5 mM MgCl2, pH 8.7, Qiagen, Milano, Italy), 1.5 mM MgCl2,
400 μM of each deoxynucleotide, 5 μM of each primer except
for the 2 GEFCα primers that were added at 2.5 μM, 2.5 U Taq
polymerase (Qiagen), and 400 ng of genomic DNA. PCR was
performed in a Applied Biosystems 2720 thermal cycler at 94°
C for 5 minutes for initial denaturation, followed by 28 cycles of
94°C for 30 seconds, 70°C for 10 seconds, 72°C for 30 sec-
onds, with a ﬁnal extension step at 72°C for 5 minutes. PCR
products were separated on a 1.8% agarose gel at 70 V for 2
hours 30 minutes.
Twenty-three C. gattii strains, presenting different mating
types and serotypes, were tested to validate the method
(Table 1). In addition, 3 C. neoformans strains as well as 5
strains belonging to other yeast species were included in the
study to evaluate the speciﬁcity of the primers (Table 1).
Genomic DNA was extracted from each strain as previously
described [17].
All of the PCR products obtained by the multiplex PCR were
of the expected size determined during the primers design.
Ampliﬁcation of serotype B-MATα strains yielded a 530-bp
amplicon, serotype C-MATα strains a 504-bp amplicon, sero-
type B-MATa strains a 322-bp amplicon, and the serotype C-FIG. 1. (a) Sequences of the primers used in the multiplex polymerase chain r
representative strains of each sero-mating type. (c) Ampliﬁcation of simula
Molecular ladders: GelPilot 100 bp plus (Qiagen, Milano, Italy) and PCR 20 b
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InMATa strain a 284-bp amplicon. Nonspeciﬁc products or cross
reactions were not observed (Fig. 1b). Ampliﬁcation of
C. neoformans strains and other species did not produce any
amplicon conﬁrming the species speciﬁcity of the primers.
In addition, C. gattii hybrid strains were simulated by mixing,
in equal quantity, the genomic DNA in different allelic combi-
nations. The results showed that the multiplex PCR was able to
discriminate the different allelic combinations and it was suit-
able to identify putative C. gattii hybrids (Fig. 1c).
The multiplex PCR here described presents some advantages
compared to other methods recently reported in the literature.
Ito-Kuwa et al. [18] developed a multiplex system able to
discriminate the 5 Cryptococcus serotype alleles but not the
mating types. In addition, this method does not identify the
different hybrid combinations. Other authors [19] reported a
method based on 2 multiplex PCRs to distinguish the sero-
mating type allelic pattern of C. neoformans isolates. On the
contrary, the method cannot be used to type C. gattii isolates.
Finally, Feng et al. [20] described a PCR restriction fragment
length polymorphism system able to identify simultaneously the
molecular type and the mating type of both Cryptococcus spe-
cies. However, the method requires the ampliﬁcation of 2
genes (CAP1 and GEF1) and further steps of digestion with
different restriction enzymes, and therefore it is cumbersome
to apply in the screening of a large number of isolates. In
addition, it is not able to discriminate between serotype B and
serotype C alleles.eaction (PCR). (b) Multiplex PCR results obtained by the ampliﬁcation of
ted hybrid samples containing DNA mixed in different combinations.
p low ladder (Sigma Aldrich, Milano, Italy).
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TABLE 1. List of the strains used in this study
Strain
Geographical
origin Source Species Serotype
Molecular
type
Mating
type Reference
WM137 (UCLA384) California, USA Human C. gattii C VGIII α W. Meyer
NIH312 (ATCC34880) USA Human C. gattii C VGIII α K.J. Kwon-Chung
WM779 South Africa Cheetah C. gattii C VGIV α W. Meyer
NIMH103 Bangalore, India Human, CSF C. gattii C VGIV α C. Nagarathna
NIMH114 Bangalore, India Human, CSF C. gattii C VGIV α C. Nagarathna
NIMH118 Bangalore, India Human, CSF C. gattii C VGIV α C. Nagarathna
NIMH155 Bangalore, India Human, CSF C. gattii C VGIV α C. Nagarathna
WM163 Gold Coast, Australia Eucalyptus C. gattii B VGI α W. Meyer
WM201 Balranald, Australia Eucalyptus C. gattii B VGI α W. Meyer
IUM 91-6492 Shanghai, China Human, CSF C. gattii B VGI α Wen Hai
IUM 92-6957 Shanghai, China Human, CSF C. gattii B VGI α Wen Hai
IUM 94-6315 Shanghai, China Human, CSF C. gattii B VGI α Wen Hai
IUM 92-6682 Italy/Brazila Human, CSF C. gattii B VGII α IUM collection
IUM 98-1969 Athens, Greece Human, BAL C. gattii B VGII α A. Velegraki
IUM 01-4731 Athens, Greece Human, CSF C. gattii B VGII α A. Velegraki
IP189 Paris, France Human C. gattii B VGIII α Institut Pasteur
B3939 (RV20186) USA Human, CSF C. gattii B VGI α K.J. Kwon-Chung
IUM 00-5363 Athens, Greece Human, skin C. gattii B VGII a A. Velegraki
IUM 95-4427 Italy Human, CSF C. gattii B VGI a M.T. Montagna
IUM 96-2791 Italy Environment C. gattii B VGI a M.T. Montagna
IUM 96-2817 Italy Environment C. gattii B VGI a M.T. Montagna
NIH198 USA Human C. gattii B VGIII a K.J. Kwon-Chung
NIH191 (ATCC32608) California, USA Human C. gattii C VGIII a K.J. Kwon-Chung
H99 USA Human C. neoformans var. grubii A VNI α K.J. Kwon-Chung
JEC21 USA Lab strain C. neoformans var. neoformans D VNIV α K.J. Kwon-Chung
IUM 10-0288 Italy Human, blood C. neoformans AD hybrid AD VNIII aα IUM collection
IUM 00-1143 Italy Human, pharyngeal
swab
C. albidus – – – IUM collection
CBS570 The Netherlands Human, sputum C. curvatus – – – CBS collection
IUM 89-6273 Italy Human C. laurentii – – – IUM collection
IUM 90-3093 Italy Human, rectal swab C. uniguttulatus – – – IUM collection
IUM 09-0225 Italy Human, blood Candida albicans – – – IUM collection
UCLA, University of California, Los Angeles, CA, USA; NIMH, NIMHANS, Bangalore, India; WM, Westmead Millennium Institute, Sydney, Australia; IUM, Dip. Scienze Biomediche
per la Salute, Università degli Studi, Milano, Italy; IP, Institut Pasteur, Paris, France; NIH, National Institutes of Health, Bethesda, MD, USA; CBS, CBS-KNAW Fungal Biodiversity
Centre, Utrecht, The Netherlands; RV, Raymond Vanbreuseghen collection at CBS-KNAW, Utrecht, The Netherlands; ATCC, American Type Culture Collection, Manassas, VA,
USA; CSF, cerebrospinal ﬂuid; BAL, bronchoalveolar lavage.
aBrazilian patient resident in Italy.
190.e3 Clinical Microbiology and Infection, Volume 21 Number 2, February 2015 CMIIn conclusion, the multiplex PCR method here described is a
useful 1-step PCR for sero-mating typing of C. gattii isolates,
capable of identifying all sero-mating allelic patterns including
hybrid combinations. Coupled with the previously developed
multiplex PCR method [16] for C. neoformans, it also could be
useful to identify the interspecies hybrids (C. neoformans× C. gattii)
determining their correct hybrid combination.
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